Article Text

Download PDFPDF
Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease–The Authors' response
  1. Walter Reinisch1,
  2. Eduard F Stange2,
  3. on behalf of the International AZT-2 Study Group
  1. 1Abteilung Gastroenterologie und Hepatologie, Universitätsklinik für Innere Medizin III, Vienna, Austria
  2. 2Robert-Bosch Krankenhaus, Innere Medizin I, Stuttgart, Germany
  1. Correspondence to Walter Reinisch, Universitätsklinik für Innere Medizin III, Waehringer Guertel 18–20, Vienna A-1090, Austria; walter.reinisch{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Dr Ford for his comments1 on our recent paper in Gut entitled ‘Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy multi-centre trial’.2 With regard to our power calculation assuming a difference in treatment effect of 35% in favour of azathioprine, although two previous …

View Full Text


  • Linked articles 218941.

  • Competing interests WR has received an unrestricted grant from Dr Falk Pharma GmbH. EFS has received speaker's honoraria.

  • Provenance and peer review Not commissioned; not externally peer reviewed.

Linked Articles